Inhibition of acyl-CoA binding protein (ACBP) by means of a GABAARγ2-derived peptide
Gerasimos Anagnostopoulos, Ester Saavedra, Flavia Lambertucci, Omar Motiño, Jordan D. Dimitrov, David Roiz‐Valle, Vı́ctor Quesada, Karla Alvarez-Valadez, Hui Chen, Allan Sauvat, Rong Yan, Uxía Nogueira-Recalde, Sijing Li, Léa Montégut, Mojgan Djavaheri‐Mergny, Maria Castedo, Carlos López-Otı́n, Maria Chiara Maiuri, Isabelle Martins, Guido Kroemer
Abstract
Abstract Acyl-CoA binding protein (ACBP) encoded by diazepam binding inhibitor (DBI) is an extracellular inhibitor of autophagy acting on the gamma-aminobutyric acid A receptor (GABA A R) γ2 subunit (GABA A Rγ2). Here, we show that lipoanabolic diets cause an upregulation of GABA A Rγ2 protein in liver hepatocytes but not in other major organs. ACBP/DBI inhibition by systemically injected antibodies has been demonstrated to mediate anorexigenic and organ-protective, autophagy-dependent effects. Here, we set out to develop a new strategy for developing ACBP/DBI antagonists. For this, we built a molecular model of the interaction of ACBP/DBI with peptides derived from GABA A Rγ2. We then validated the interaction between recombinant and native ACBP/DBI protein and a GABA A Rγ2-derived eicosapeptide (but not its F77I mutant) by pull down experiments or surface plasmon resonance. The GABA A Rγ2-derived eicosapeptide inhibited the metabolic activation of hepatocytes by recombinant ACBP/DBI protein in vitro. Moreover, the GABA A Rγ2-derived eicosapeptide (but not its F77I-mutated control) blocked appetite stimulation by recombinant ACBP/DBI in vivo, induced autophagy in the liver, and protected mice against the hepatotoxin concanavalin A. We conclude that peptidomimetics disrupting the interaction between ACBP/DBI and GABA A Rγ2 might be used as ACBP/DBI antagonists. This strategy might lead to the future development of clinically relevant small molecules of the ACBP/DBI system.